ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease

Add to your list(s) Download to your calendar using vCal

• Dr. Ta Yuan Chang, Geisel School of Medicine at Dartmouth, Hanover, United States
• Thursday 23 February 2017, 15:30-16:00
• Online.

If you have a question about this talk, please contact Ilana Spilka.

Late onset Alzheimer’s disease (LOAD) is the most prevalent form of dementia, and it has no cure at present. Cholesterol metabolism is closely associated with AD at several stages. Cholesterol ester (CE) is the storage form of cholesterol. A causal relationship exists between LOAD and increased CE content in the brain. Acyl-CoA:cholesterol acyltransferase 1 (ACAT1) converts free cholesterol to cholesteryl esters in various tissues including the brain. Here I review the recent evidence that implicates ACAT1 as a potential therapeutic target for AD. I also discuss the potential usage of various ACAT inhibitors currently available to treat AD.

This talk is part of the Meeting the Challenge of Healthy Ageing in the 21st Century series.

This talk is included in these lists:

• Meeting the Challenge of Healthy Ageing in the 21st Century
• Online

Note that ex-directory lists are not shown.